Case Report
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Clin Cases. Aug 16, 2013; 1(5): 166-168
Published online Aug 16, 2013. doi: 10.12998/wjcc.v1.i5.166
Long lasting response to second-line everolimus in kidney cancer
Antonella Virtuoso, Tania Policastro, Michela Izzo, Piera Federico, Carlo Buonerba, Pasquale Rescigno, Giuseppe Di Lorenzo
Antonella Virtuoso, Tania Policastro, Michela Izzo, Piera Federico, Carlo Buonerba, Pasquale Rescigno, Giuseppe Di Lorenzo, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica, Università degli Studi Federico II, 80131 Naples, Italy
Giuseppe Di Lorenzo, Deparment of Clinical Medicine, University Federico II of Naples, 80131 Naples, Italy
Author contributions: Virtuoso A, Policastro T, Izzo M and Buonerba C wrote the paper; all authors treated and followed up the patient, and gave their final approval to the manuscript.
Correspondence to: Giuseppe Di Lorenzo, MD, PhD, Deparment of Clinical Medicine, University Federico II of Naples, Via Pansini, 5, 80131 Naples, Italy. giuseppedilorenzoncol@hotmail.com
Telephone: +39-8-17462114 Fax: +39-8-17462114
Received: May 1, 2013
Revised: July 2, 2013
Accepted: July 17, 2013
Published online: August 16, 2013
Processing time: 98 Days and 9 Hours
Abstract

In the case presented here, everolimus was administered after first line therapy with sunitinib in a patient with metastatic renal cell carcinoma. The safety profile was excellent. The prolonged progression-free survival (PFS) obtained with everolimus in this case is of peculiar interest, as it is a multiple of the median PFS obtained in with everolimus in the regulatory trial. Such finding suggests that a subset of patients with renal cell carcinma may particularly benefit from everolimus.

Keywords: Metastatic renal cell carcinoma; Everolimus (RAD001); Sunitinib; Progression-free survival

Core tip: Everolimus (RAD001) is an orally administered inhibitor of the mammalian target of rapamycin pathway. Everolimus is recommended for the second line therapy of metastatic renal cell carcinoma after a Tyrosine kinase inhibitor. In the case presented here, everolimus was administered after first line therapy with sunitinib. The prolonged progression-free survival (PFS) obtained with everolimus in this case is of peculiar interest, as it is a multiple of the median PFS obtained in with everolimus in the regulatory trial.